Month: September 2025

Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025. Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the Company’s strong growth momentum. Fabrice Chouraqui, Chief Executive Officer, commented: “Pharming’s inclusion in the AMX mid cap index reflects our financial and pipeline growth momentum. It will further increase our visibility and attractiveness to investors. Looking forward, we remain focused on executing on our significant commercial and pipeline catalysts...

MCH GROUP INCREASES HALF-YEAR PROFIT AND STRENGTHENS PROFITABILITY  MCH Group closed the first half of 2025 with an increase in earnings. Despite lower revenues, profitability improved further – clear evidence of the implementation of efficiency measures.  For the third consecutive time, following years of losses, MCH Group reported a positive half-year result. Despite a slight decline in revenue, profitability increased markedly: net profit amounted to CHF 5.3 million, operating income to CHF 222.4 million, while EBITDA rose to CHF 18.9 million – an increase of CHF 3.6 million compared to the prior-year period. This confirms the positive impact of MCH Group’s efficiency measures, which streamlined structures and processes and reduced the cost base. At the same time, new opportunities have been opened in Basel and internationally...

Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company StatusFaraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company StatusUpholding its principles of “no further reverse stock splits” and prudent equity issuances, the Company is committed to protection of stockholder interests.  Over the past year, FF has made significant progress in system development and financial management, as well as advancing its core strategies and businesses, achieving substantial improvements in both business fundamentals and capital fundamentals.  YT Jia executes additional stock purchase under...

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stock at a public offering price of $32.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately...

SOMPO uses Radar to accelerate data-driven management across pricing, underwriting and portfolio optimization, and with Sompo Direct Insurance Inc. implementing Radar as its rate calculation engine. TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, and Sompo Holdings, Inc., one of Japan’s leading insurance groups, today announced a global partnership to deploy WTW’s Radar technology across SOMPO Group. This marks the first global agreement for Radar in Japan with Sompo Direct Insurance Inc., a member of the SOMPO Group, already implementing Radar as part of its efforts to improve automobile insurance pricing since June this year. Sompo Direct specialises in providing online automobile insurance, providing its customers with easy to understand, fast and reliable...

BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being sold by Rapport. In addition, Rapport has granted the underwriters a 30-day option to purchase up to an additional 1,442,307 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses,...

New York, NY, Sept. 09, 2025 (GLOBE NEWSWIRE) — Trailblazer Acquisition Corp. (the “Company”) announced today the pricing of its upsized initial public offering of 24,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading on September 10, 2025, under the ticker symbol “BLZRU.” Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis. BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study1) is the first registration-enabling study to evaluate whether the combination of MRI2 and PSMA-PET3 imaging can improve sensitivity, specificity, and positive and negative predictive values in diagnosing prostate cancer. The aim of the study is to demonstrate that some patients can be effectively stratified to either avoid a biopsy altogether or undergo a single PSMA-PET guided biopsy...